Achmea Investment Management B.V. Acquires 67,362 Shares of Boston Scientific Co. (NYSE:BSX)

Achmea Investment Management B.V. increased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 92.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 140,373 shares of the medical equipment provider's stock after purchasing an additional 67,362 shares during the quarter. Achmea Investment Management B.V.'s holdings in Boston Scientific were worth $12,538,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of BSX. Adero Partners LLC boosted its position in Boston Scientific by 3.3% during the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 120 shares during the period. Grove Bank & Trust lifted its stake in shares of Boston Scientific by 4.4% during the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock worth $261,000 after buying an additional 122 shares during the last quarter. PFG Investments LLC lifted its stake in shares of Boston Scientific by 1.6% during the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock worth $725,000 after buying an additional 125 shares during the last quarter. Stonegate Investment Group LLC boosted its holdings in shares of Boston Scientific by 1.6% during the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider's stock worth $699,000 after buying an additional 126 shares during the period. Finally, MinichMacGregor Wealth Management LLC grew its stake in Boston Scientific by 2.3% in the 4th quarter. MinichMacGregor Wealth Management LLC now owns 5,689 shares of the medical equipment provider's stock valued at $508,000 after buying an additional 130 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Boston Scientific

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the transaction, the executive vice president now owns 25,443 shares of the company's stock, valued at $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 137,302 shares of company stock valued at $14,319,269. 0.50% of the stock is currently owned by insiders.

Boston Scientific Price Performance

NYSE BSX traded up $1.86 on Monday, hitting $99.02. 5,703,033 shares of the company's stock were exchanged, compared to its average volume of 5,721,651. Boston Scientific Co. has a 52 week low of $66.16 and a 52 week high of $107.17. The stock has a 50-day moving average of $101.21 and a 200-day moving average of $91.97. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a market cap of $146.14 billion, a price-to-earnings ratio of 79.22, a P/E/G ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BSX shares. Stifel Nicolaus raised their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Wells Fargo & Company boosted their price target on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, Argus set a $130.00 target price on Boston Scientific in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.